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ABSTRACT  
The clinical impact and accessibility of 68Ga tracers for the prostate-specific membrane 
antigen (PSMA) and other targets would be greatly enhanced by the availability of a 
simple, one-step kit-based labeling process. Radiopharmacy staff are accustomed to 
such procedures in the daily preparation of 99mTc radiopharmaceuticals. Currently, 
chelating agents used in 68Ga radiopharmaceuticals do not meet this ideal. Aim: To 
develop and evaluate preclinically a 68Ga radiotracer for imaging PSMA expression 
that could be radiolabeled simply by addition of 68Ga generator eluate to a cold kit. 
Methods: A conjugate of a tris(hydroxypyridinone) (THP) chelator with the 
established urea-based PSMA inhibitor was synthesized and radiolabeled with 68Ga by 
adding generator eluate directly to a vial containing the cold precursors THP-PSMA 
and sodium bicarbonate, with no further manipulation. It was analyzed after 5 
min by instant thin layer chromatography (iTLC) and high performance liquid 
chromatography (HPLC). The product was subjected to in vitro studies to determine 
PSMA affinity using PSMA-expressing DU145-PSMA cells, with their non-expressing 
analog DU145 as a control. In vivo positron emission tomography (PET) imaging and 
ex vivo biodistribution studies were carried out in mice bearing xenografts of the same 
cell lines, comparing with 68Ga-HBED-CC-PSMA. Results: Radiolabeling was 
complete (>95%) within 5 min at room temperature, showing a single radioactive 
species by HPLC that was stable in human serum for >6 hours and showed specific 
binding to PSMA-expressing cells (IC50 of 361 ± 60 nM). In vivo PET imaging showed 
specific uptake in PSMA-expressing tumors, reaching 5.6 ± 1.2 % ID/cm3 at 40-60 min 
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and rapid clearance from blood to kidney and bladder. The tumor uptake, 
biodistribution and pharmacokinetics were not significantly different to those of 68Ga-
HBED-CC-PSMA except for reduced uptake in the spleen. Conclusion: 68Ga-THP-
PSMA has equivalent imaging properties but greatly simplified radiolabeling 
compared to other 68Ga-PSMA conjugates. THP offers the prospect of rapid, simple, 
one-step, room temperature “syringe-and-vial” radiolabeling of 68Ga 
radiopharmaceuticals. 
KEY WORDS: PSMA receptor, PET imaging, gallium chelators, prostate cancer, 
radiopharmaceutical kit. 
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INTRODUCTION 
Infrastructure in radiopharmacies has been developed around 99mTc labeling protocols, 
where a generator is eluted multiple times per day to produce diverse tracers by 
reconstituting commercially available “cold kits” compatible with good manufacturing 
practice (1).This is typically a high-throughput environment where speed, simplicity, 
volume and reproducibility of radiolabeling are paramount. The growth of 18F and 11C 
PET tracers, with which a kit model is not compatible due to the need for an on-site 
cyclotron and more complex synthetic chemistry, has spawned more diverse, complex 
and costly infrastructure to support PET. Nevertheless the generator and kit approach 
retains its appeal and in principle, 68Ga generators compatible with good manufacturing 
practice now available are amenable to kit production if a simple, mild chelation step 
can be achieved (2,3). This would make 68Ga tracers widely available without the 
complex and costly infrastructure associated with 18F and 11C tracer production. 
This concept was suggested more than two decades ago (4), but despite several 
recent reports of kit-based 68Ga tracer production (5,6), an ideal one-step procedure for 
68Ga radiolabeling, matching the simplicity typical of long-established 99mTc-labeling 
procedures requiring only the addition of generator eluate to the kit vial, has not yet 
been achieved. Towards this end, the chelator must meet several criteria: its labeling 
should reach completion (>95%) quickly (<5 min) at room temperature and be 
unaffected by common trace metals, without additional steps to concentrate, buffer or 
purify. Its complex should resist in vivo transchelation (e.g. by transferrin), and 
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conjugation and radiolabeling should not induce mixtures of diastereomers, 
enantiomers or geometric isomers, nor adverse pharmacokinetics e.g. delayed 
clearance or non-specific binding. The current generation of 68Ga chelators do not meet 
these criteria. For example, the widely adopted macrocycle DOTA (7), while 
complexing Ga3+ with extraordinarily high kinetic stability, has very slow complexing 
kinetics, necessitating heat (e.g. 90 oC, followed by a suitable cooling period), a large 
amount of the biomolecule, and low pH.  Low yields (<95%) necessitate a purification 
step. These factors add process complexity, limit specific activity and may damage the 
biomolecule. Conversely, the fast chelation kinetics of HBED-CC makes radiolabeling 
of 68Ga-HBED-CC-PSMA possible at room temperature, but produces an undesirable 
mixture of cis/trans geometric isomers distinguishable by HPLC (5,8,9). Thus, a 
heating step is still required, to reduce the number of isomers and increase the yield of 
one to ~ 90 % (9). Clinical radiosynthesis of tracers based on these chelators is 
currently performed on cartridge-based synthesis modules, taking 35 min and typically 
affording 80% ± 5 % decay corrected radiochemical yield (9). 
Recently, several groups have introduced new 68Ga3+ chelators that address 
these issues but none eliminate all of them. NOTA, TRAP and DEDPA are promising 
but, like DOTA, require acidic conditions, and are vulnerable to competition from 
contaminating trace metals. The DATA series of chelators show rapid, room 
temperature labeling at pH 5; the DATAPPh variant can be labeled in 15 min at pH 7 
but requires preprocessed eluate (10). A class of chelator that promises to meet the 
requirements for kit-based labeling is the THP system; it can complex 68Ga rapidly at 
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room temperature and neutral pH, with high yield and purity. Its performance has 
previously been evaluated against a range of common chelators (11), including HBED, 
demonstrating superior radiolabeling properties under milder conditions. THP has also 
been functionalized for conjugation to peptides and proteins while retaining the 
required mild radiolabeling and in vivo targeting properties (11-15). 
Here we evaluate a THP bioconjugate targeting PSMA (over-expressed in 
prostate cancer), incorporating a small urea-linked dipeptide pharmacophore (7,8,16) 
(Fig.1). A 68Ga-labeled conjugate of this targeting moiety with HBED-CC has shown 
outstanding clinical promise in several trials in patients with prostate cancer (17,18), 
but is subject to the production difficulties outlined above. The aims of this work were 
to determine the potential of 68Ga-THP-PSMA to achieve one-step kit-based labeling 
of a radiopharmaceutical intended for PSMA imaging, and to evaluate preclinically the 
resulting tracer. 
MATERIALS AND METHODS 
Synthesis of THP-PSMA 
THP-PSMA was synthesized as described in the Supplemental data. 
Preparation of Lyophilized Kits 
Kits for one-step radiolabeling were prepared by lyophilizing an aqueous 
solution (5.25 mL) containing sodium bicarbonate (44 mg), sodium phosphate 
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monobasic (8.6 mg), sodium phosphate dibasic heptahydrate (8.9 mg) and THP-PSMA 
(40 µg, 26 nmol) in a plastic vial affording a white powder. 
68Ga-THP-PSMA Radiolabeling  
Radiolabeling and radioanalysis (HPLC and iTLC) of 67/68Ga-DOTA-PSMA 
(PSMA-617) (8), 67/68/natGa-HBED-CC-PSMA (DKFZ-PSMA-11) (9,10), and 67/natGa-
THP-PSMA are described in Supplemental data. 
Initial 68Ga radiolabeling optimization was performed with an Eckert and 
Ziegler (E&Z Radiopharma GmbH) 68Ge/68Ga generator producing 120 – 400 MBq 
68Ga. Eluates (0.1 M HCl, 5 mL, Sigma Aldrich HPCE grade) were fractionated (10 × 
0.5 mL) but not preconditioned to concentrate 68Ga or remove trace metal 
contaminants. Typically, 68Ga3+ (5-75 MBq, 250 µL of the hottest fraction) was added 
to a mixture containing THP-PSMA in a range of concentrations (5-0.01 µg in 3 µL) in 
sodium bicarbonate solution (1 M, 26 µL) producing a solution with a pH of 6.5-7.5. 
Radiochemical yield was evaluated after 5 min at room temperature using HPLC and 
iTLC. HPLC: 68Ga-THP-PSMA Rt = 10.9 min; unbound 68Ga Rt = 2.32 min. iTLC: 
68Ga-THP-PSMA Rf = 0.8-1; unbound 68Ga Rf = 0. For in vivo studies THP-PSMA (2 
µg) was labeled with 68Ga as described above; >95% radiochemical purity was 
consistently achieved. 
To evaluate labeling using the entire eluate without fractionation, E&Z 
68Ge/68Ga generator eluate (5 mL 0.1M HCl, 122-202 MBq) or Galli EO (IRE ELiT) 
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68Ge/68Ga generator eluate (1.1 ml eluate diluted to 5 mL with 0.1 M HCl, 600-660 
MBq) as added directly into a vented freeze-dried kit vial. After mixing, carbon 
dioxide evolution visibly ceased after 15 s, providing a transparent, colorless solution 
at pH 6-7 with a final concentration of 5.25 µM THP-PSMA. iTLC was performed 5 
min and HPLC 10 min after reconstitution. Decay-corrected radiochemical yield 
determined by each method was >95% (n = 3 per generator). 
Log POCT/PBS 
67Ga labeled radiotracer (50 µL, 10 M, specific activity 1.5 MBq/nmol) was 
added to a pre-equilibrated mixture of 500 µL octanol and 450 µL phosphate-buffered 
saline. The mixture was mixed for 30 min, and the phases separated by centrifugation 
(10,000 rpm, 10 min). Aliquots from each phase were gamma-counted. 
Serum Stability 
68Ga-THP-PSMA was labeled at 5 MBq/nmol as described above. 20 µL was 
added to 180 µL human serum giving a final THP-PSMA concentration of 2.5 µM. 
Samples were incubated at 37°C and monitored over 6 h by size exclusion HLPC 
(details in Supplemental data). 68Ga-THP-PSMA without serum and unchelated 68Ga3+ 
incubated with serum were analyzed similarly. 
Cell Uptake and Binding Affinity Assays 
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To determine the cellular uptake of each tracer at 37°C and 4°C over time, and 
whether a plateau (equilibrium) state is reached, PSMA-expressing cells DU145-
PSMA and non-PSMA-expressing cells DU145 (19) were seeded in a 24-well plate 
(0.25 x 106 cells/well), one day before the assay. Two minutes before incubation the 
medium was replaced with 245 µL fresh medium at 37°C or 4°C, then 5 µL of one of 
the 67Ga PSMA tracers (specific activity 0.75-2.2 MBq/nmol) was added giving a final 
concentration of 1 nM. Plates were incubated at 37°C or 4°C. At each time point 
supernatant was removed and cells were washed with 3 × 0.25 mL phosphate-buffered 
saline to determine the unbound fraction, followed by an acid wash (0.5 M glycine, pH 
2.5, at 4°C, 5 min) to determine cell surface-bound activity. Cells were lysed with 1 M 
NaOH to determine activity internalized by the cells. Fractions were gamma counted.  
To determine the IC50, competitive binding studies were performed with 
DU145-PSMA cells with 1 nM 68Ga-DOTA-PSMA as the probe, blocking with natGa-
THP-PSMA or natGa-HBED-CC-PSMA over a range of concentrations. Full details are 
described in Supplemental data.  
Due to poor solubility of natGa-THP-PSMA above 0.25 mM, an alternative 
measure of affinity was developed, allowing the relative affinity of two gallium PSMA 
tracers to be determined simultaneously without the natGa complex, mitigating 
solubility difficulties and minimizing variance across samples arising from different 
cell numbers or radiotracer batches. Two different PSMA tracers, one labeled with 
67Ga and the other with 68Ga, were simultaneously incubated with DU145-PSMA cells 
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in a single well at 4°C for 2 h (non-internalizing conditions selected to best represent 
the equilibrium state from the cell uptake studies). The tracers compared were: 67/68Ga-
DOTA-PSMA, 67/68Ga-HBED-CC-PSMA, and 67/68Ga-THP-PSMA. Each 67Ga tracer 
was compared to each 68Ga tracer and affinity ratios were obtained by measuring total 
and non-specific binding for each tracer (gamma counting) and calculating the ratio of 
their specific binding. Full details are provided in the Supplemental data. 
Mouse Model of Prostate Cancer 
Animal studies complied with UK Research Councils’ and Medical Research 
Charities’ guideline on responsibility in the use of animals in bioscience research, 
under UK Home Office project and personal licenses. Subcutaneous prostate cancer 
xenografts were produced in SCID/beige mice (male, 5-12 weeks) by injecting 4 × 106 
DU145-PSMA or DU145 cells in the right flank. Imaging was undertaken once the 
tumor had reached 5-10 mm in diameter (1-4 weeks after inoculation). 
PET Scanning 
PET imaging was performed on four groups of mice (n = 3 each) under 
isoflurane anesthesia with a BioScan nanoPET-CT PLUS (Mediso, Hungary). Mice 
were CT imaged before radiotracer administration and dynamic PET data were 
collected for the first hour post-injection. Mice were then euthanized and organs 
harvested, weighed and gamma-counted. Mice bearing DU145-PSMA tumors were 
administered either 68Ga-THP-PSMA (5-15 MBq, 50-140 μL, 0.4-0.9 µg, group 1) or 
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68Ga-HBED-CC-PSMA (5-15 MBq, 50-140 μL, 0.6-1.3 µg, group 2) by tail vein 
injection. A third group (group 3) were co-administered 68Ga-THP-PSMA and the 
PSMA-inhibitor 2-(phosphonomethyl)pentane-1,5-dioic acid (PMPA) (50 µg, Enzo 
Life Sciences) (20,21). Mice bearing DU145 tumors were administered 68Ga-THP-
PSMA (group 4). Imaging protocol and image analysis methods are described in the 
Supplemental data. 
Statistical Analysis 
Data were analyzed in GraphPad Prism 5 (version 5.04) and expressed as mean 
± SD. Student t-tests were used to determine statistical significance with P < 0.05 
considered significant.  
RESULTS 
Synthesis of THP-PSMA 
Supplementary Figure 1 shows the route used to synthesize THP-PSMA. The 
resin-bound PSMA inhibitor (compound 7) was prepared by in situ formation of a 
bis(tert-butyl) glutamate isocyanate (compound 5) followed by coupling with resin-
bound protected lysine (compound 3). After deprotection and coupling with glutaric 
anhydride, the intermediate bearing a pendant carboxylate (compound 8) was activated 
and formed an amide bond with the free amine of a THP derivative (22). Cleavage 
from the solid support and glutamate deprotection using trifluoro acetic acid formed 
THP-PSMA (Fig. 1). Purification by semi-preparative HPLC afforded THP-PSMA as 
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a trifluoro acetic acid salt, yield 4 mg, 2.6 µmol, 5.2% yield from resin loading; 
(C54H77N11O19.(CF3COO)3) MW 1526.33,. HPLC: Rt = 13.4 min, >98% purity. LC-
ESI-MS, 1H and 13C NMR data are shown in Supplemental Table 1.  
Radiolabeling 
The THP chelator enabled radiolabeling with unmodified generator eluate, in a 
single step. 68Ga3+ (5-75 MBq) in aqueous HCl (0.1 M, 250 µL) was added to pre-
prepared THP-PSMA (5-0.01 µg in 3 µL H2O) in sodium bicarbonate solution (1 M, 
27 µL). After five minutes pH was 6.5-7.5. Radiochemical purity, determined by 
HPLC and iTLC as a function of THP-PSMA concentration is shown in Figure. 2. 
Specific activities between 15 and 45 MBq/nmol were consistently achieved with the 
labeling conditions used for in vivo work (2 µg, 1.3 nmol THP-PSMA, 250 µL 20-60 
MBq 68Ga eluate, >95% radiochemical purity). 
One-step Kit for Radiolabeling 
Using kit vials containing lyophilized THP-PSMA (40 g, 26 nmol), sodium 
bicarbonate (44 mg) and sodium phosphate buffer (17.5 mg), radiosynthesis of 68Ga-
THP-PSMA was achieved in one step by direct addition of 5 mL of generator eluate 
(0.1 M HCl, 122-202 MBq from the E&Z generator or 600-660 MBq from the IRE 
generator). After five minutes, the pH was 6-7 and iTLC confirmed radiochemical 
purity above 95% with specific activities of up to 22 MBq/nmol using the IRE 
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generator (Fig. 2; Supplemental Fig. 2). iTLC analysis up to 3 h post-reconstitution 
showed no instability or autoradiolysis (Supplemental Fig. 2). 
Lipophilicity and Serum Stability 
The log POCT/PBS values of the three 68Ga-PSMA complexes at pH 7.4 were 
very similar: -5.35 ± 0.1 for 67Ga-THP-PSMA (n = 6), -5.40 ± 0.2 for 67Ga-HBED-CC-
PSMA (n = 6) and -5.40 ± 0.1 for 67Ga-DOTA-PSMA (n = 5), indicating that all 
tracers are hydrophilic and lipophilicity is unlikely to underlie differences in in vivo 
performance. In serum 68Ga-THP-PSMA (Supplemental Fig.3) showed minimal 
transchelation (<2%) to proteins after 6 h incubation. 
In Vitro Cell Uptake and Binding Affinity Assays 
Uptake of 67Ga-DOTA-PSMA, 67Ga-HBED-CC-PSMA and 67Ga-THP-PSMA 
in DU145-PSMA and DU145 cells at 37°C and 4°C is shown in Figures 3A and 
Supplemental Figure 4. All three tracers showed time-dependent accumulation in 
PSMA-expressing cells, but very low uptake in non-PSMA-expressing cells, 
confirming uptake is PSMA-mediated. At 37°C uptake continued to increase with 
time, preventing measurement of equilibrium binding parameters such as Kd, but at 
4°C, a plateau was reached for all tracers after approximately 2 h. Relative affinity was 
therefore measured after 2 h at 4°C. Results showed the Kd of 67/68Ga-THP-PSMA was 
10.4 ± 3.4 times higher than that of 67/68Ga-HBED-CC-PSMA and 8.6 ± 3.4 times that 
of 67/68Ga-DOTA-PSMA, in agreement with directly measured IC50 values of Ga-THP-
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PSMA (361 ± 60 nM) and Ga-HBED-CC-PSMA (34.3 ± 4.1 nM) (Fig. 3B and 
Supplemental Fig. 5). 
PET Imaging and Biodistribution 
PET/CT scanning of 68Ga-THP-PSMA in SCID/beige mice bearing PSMA-
positive xenografts (DU145-PSMA, group 1) showed that excretion of 68Ga-THP-
PSMA was rapid and exclusively renal, with the majority of activity associated with 
bladder and kidneys by 60 min (Fig. 4 and Supplemental Fig. 6). Blood clearance, 
represented by blood pool in the left ventricle, was rapid, decreasing to 1% ID/cm3 
within 30 min (Fig. 5B). With images scaled between 0 and 25% ID/cm3, tumors were 
clearly delineated (Fig. 4). Analysis of the 40-60 min post-injection (PI) images gave a 
tumor uptake value of 5.6 ± 1.2 % ID/cm3 (Fig. 5B). Specificity was confirmed both by 
mice bearing a PSMA-negative but otherwise similar tumor (DU145, group 4) with 
uptake of 1.5 ± 1.2 % ID/cm3 (p < 0.05 compared to group 1), and by blocking 
experiments in mice bearing a DU145-PSMA tumor where PMPA was co-
administered with 68Ga-THP-PSMA (group 3) giving a tumor uptake of 1.0 ± 0.4 % 
ID/cm3 (p < 0.05 compared to group 1). 
For comparison with an established PET tracer, mice bearing DU145-PSMA 
tumors were imaged with 68Ga-HBED-CC-PSMA (group 2) (8,9,17). Time activity 
curves for 68Ga-HBED-CC-PSMA (group 2) and 68Ga-THP-PSMA (group 1) showed 
very similar blood clearance, tumor uptake and renal excretion (Fig. 5). Image analysis 
of 40-60 min PET images revealed that tumor uptake of 68Ga-THP-PSMA (5.3 ± 0.1 % 
by NYU Med Ctr Lib - Periodicals Dept on April 13, 2017. For personal use only. jnm.snmjournals.org Downloaded from 
14 
 
ID/cm3) was not significantly different to that of 68Ga-HBED-CC-PSMA (5.6 ± 1.2 % 
ID/cm3). 
Ex vivo biodistribution data, summarized in Figure 5C and Supplemental Table 
2, were consistent with PET image analysis, confirming renal excretion and excellent 
specificity of 68Ga-THP-PSMA for PSMA expressing tumors. 68Ga-THP-PSMA 
showed very similar ex vivo biodistribution to 68Ga-HBED-CC-PSMA, apart from 
markedly lower spleen uptake (3.7 ± 1.3 and 17.6 ± 6.1 % ID/g respectively). 
Importantly, anesthesia appeared to severely affect tracer uptake in the kidney and 
excretion to bladder, with large variation in kidney uptake across all groups, so 
comparison of kidney and bladder activity should be interpreted with caution. 
DISCUSSION 
The aim of this study was to develop a 68Ga radiotracer that targets PSMA with simple 
and high-yielding radiolabeling procedures suitable for development into a single step 
kit-formulated radiopharmaceutical compatible with good manufacturing practice, 
requiring only addition of unprocessed, unfractionated generator eluate to a single vial. 
The latter requirement was met by incorporating THP. A THP-PSMA conjugate has 
been synthesized and characterized, and could be readily radiolabeled with 68Ga (and 
67Ga). Radiolabeling yields of >95% and specific activity 15-45 MBq/nmol with 
unprocessed generator-produced 68Ga were achieved in one step at pH 7 and ambient 
temperature within 5 min without further purification. Based on this we developed a 
lyophilized kit, which can be labeled/reconstituted simply by adding 5 mL of raw 
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generator eluate. One-step kits can only be used with generators with <0.001% 68Ge 
breakthrough; of these, the E&Z has the largest elution volume (5 mL, 0.1 M HCl) and 
the kit was designed accordingly. Within the range used, specific activity was limited 
only by the activity available from the generator; the highest observed was 22 
MBq/nmol with an elution of 660 MBq in 5 mL. Higher specific activities have been 
obtained in a clinical setting and will be reported alongside first-in-man studies. These 
radiolabeling properties demonstrate that kit-based radiolabeling of 68Ga tracers, 
analogous to the simple manipulations to which radiopharmacy staff producing 99mTc 
radiopharmaceuticals are accustomed, and requiring equipment no more complex than 
a shielded syringe and vial, is entirely feasible with an appropriate chelator. As well as 
rapid and simple radiolabeling, the coordination properties of THP endow its 
conjugates with other properties well-suited to radiopharmaceutical application. It is 
highly selective for tripositive metal ions with ionic radius similar to that of Fe3+ and 
Ga3+ (23), potentially reducing the need to remove contaminating metal ions in raw 
generator eluate. Unlike HBED-CC, the tripodal design of THP restricts the number of 
geometric isomers that form upon Ga3+ coordination: upon reverse-phase HPLC, 68Ga-
THP-PSMA elutes as a single radioactive species (Fig. 2B) shown by LCMS to be a 
1:1 complex with gallium (Supplemental Table 1). Any isomerism (such as the  
isomerism possible with tripodal complexes) is subject to equilibration that is rapid 
compared to the timescale of HPLC and in vivo processes, and hence biologically 
irrelevant. The lipophilicity is low and comparable to that of established 68Ga-PSMA 
ligands. 
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Although THP-PSMA was rationally designed based on previous literature 
(8,21,24,25), we have not yet attempted to optimize the specific target affinity of THP-
PSMA bioconjugates. In vitro experiments demonstrate that 68Ga-THP-PSMA binds 
specifically to PSMA, although with weaker affinity than 68Ga-HBED-CC-PSMA and 
68Ga-DOTA-PSMA. The simplicity of radiolabeling, excellent serum stability and in 
vitro PSMA-binding justified further evaluation of the new tracer in vivo, which 
showed that incorporation of THP into bioconjugates confers no THP-specific adverse 
pharmacokinetics. The rapid renal excretion, low non-specific uptake of 68Ga-THP-
PSMA in non-target tissues and high, specific radioactivity concentration in PSMA-
expressing tumors are clinically desirable features. In the pre-clinical model used here, 
tumor uptake and pharmacokinetic properties of 68Ga-THP-PSMA and 68Ga-HBED-
CC-PSMA are indistinguishable except that spleen uptake of 68Ga-THP-PSMA is 
lower by almost a factor of 5. Although PSMA-targeting radiopharmaceuticals 
generally appear to share high uptake in spleen in mice, murine spleen is not believed 
to express PSMA (26). It seems likely therefore that some other target capable of 
binding the PSMA tracers is present in spleen, and that 68Ga-THP-PSMA has enhanced 
ability to distinguish PSMA from this alternative target. 
CONCLUSION 
Use of THP as the 68Ga3+ chelator facilitates rapid chelation under mild 
conditions and produces a PSMA-targeted bioconjugate that can be labeled in one step 
by reconstitution of a kit with unprocessed generator eluate. Labeling requires only a 
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generator, a cold-kit vial, a syringe, quality control facilities and shielding. Kit-based 
labeling can be performed in a few minutes, using the full volume of unprocessed 
generator eluate (5 mL), without post-synthesis purification, achieving >95 % 
radiochemical purity. In vivo, 68Ga THP-PSMA accumulates in PSMA-expressing 
tumors, with good tumor to background ratios delineation of PSMA-positive tumor 
lesions similar to 68Ga-HBED-CC-PSMA. Kit-based radiolabeling of 68Ga 
radiopharmaceuticals is feasible with THP and would facilitate wider and more 
economical use of 68Ga in hospitals, hence benefitting more patients. 
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FIGURE 1. Structure of (A) DOTA-PSMA (PSMA-617) (7); (B) HBED-CC-PSMA 
(DKFZ-PSMA-11) (8,11); (C) THP-PSMA 
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FIGURE 2 (A) Dependence of radiochemical purity of 68Ga-THP-PSMA on mass of 
THP-PSMA in 280 µL, as measured by HPLC (red) and iTLC (black) after 5 min; n = 
3, mean ± SD. (B) HPLC (λ = 220 nm) of THP-PSMA (blue, RT = 13.38 min) and 
natGa-THP-PSMA (black, RT = 10.92 min, excess Ga(NO3)3 is present with RT = 1.47 
min), and radio-HPLC of 68Ga-THP-PSMA (red, RT =11.05 min) labeled using the 
one-step kit and analyzed 10 min post-reconstitution. (C) iTLC of 68Ga-THP-PSMA 
labeled using one-step kit, analyzed 5 min post-reconstitution (Rf unchelated 68Ga = 0, 
Rf 68Ga-THP-PSMA = 0.8-1). 
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FIGURE 3: (A) 67Ga-THP-PSMA uptake over time at 4°C and 37°C, 1 × 106 cells/mL 
with DU145-PSMA or DU145 cells. (B) Representative IC50 experiment for natGa-
THP-PSMA (black) or natGa-HBED-CC-PSMA (blue) with 1 nM 68Ga-DOTA-PSMA 
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as the probe (n = 3 for each concentration). IC50 values in main text are the mean of at 
least 3 experiments (C) Ratio of Kd of two tracers incubated at 1 nM with DU145-
PSMA cells at 4°C for 2 h. The ratios were calculated from the specific binding 
obtained by incubating the 67Ga version of a tracer in the same well as the 68Ga version 
of its comparator, and vice versa. Total wells (n = 34) for comparison of 67/68Ga-THP-
PSMA with 67/68Ga-HBED-CC-PSMA or 67/68Ga-DOTA-PSMA and n = 18 for 
comparison of 67/68Ga-HBED-CC-PSMA with 67/68Ga-DOTA-PSMA; mean ± SD. 
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FIGURE 4. Representative PET/CT images of mice bearing xenografts at 40-60 min 
PI with PET images scaled from 0-25 % ID/cm3. (A) 68Ga-THP-PSMA in DU145-
PSMA tumor (group 1); (B) 68Ga-THP-PSMA in DU145 tumor (group 4); (C) 68Ga-
THP-PSMA in DU145-PSMA tumor blocked with PMPA (group 3); (D) 68Ga-HBED-
CC-PSMA in DU145-PSMA tumor (group 2).  
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FIGURE 5. (A)  PET/CT–derived % ID/cm3 in tumor and tumor/blood and 
tumor/muscle ratio 40-60 min PI. 68Ga-THP-PSMA in DU145-PSMA tumor (black), 
68Ga-THP-PSMA in DU145-PSMA tumor blocked with PMPA (hatched), 68Ga-THP-
PSMA in DU145 tumor (gray) or 68Ga-HBED-CC-PSMA in DU145-PSMA tumor 
(white); (n = 3, mean ± SD); (B) PET-derived time-activity curves of mice bearing 
DU145-PSMA tumors, imaged with 68Ga-THP-PSMA for 1 h PI: blood pool (left 
ventricle) (red), tumor (blue) and leg muscle (black); (n = 3, mean ± SD). (C) Ex vivo 
biodistribution of 68Ga-THP-PSMA in mice with a DU145-PSMA (white) or a DU145 
tumor (gray), culled 1 hour post injection (n = 3, mean ± SD). Unlike PET-imaged 
animals, these mice were not anesthetized between injection and euthanasia. 
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Supplemental Data 
68Ga-THP-PSMA: a PET imaging agent for prostate cancer offering rapid, room 
temperature, one-step kit-based radiolabeling 
Jennifer D. Young1, Vincenzo Abbate2, Cinzia Imberti1, Levente K. Meszaros1, 
Michelle T. Ma1, Samantha Y. A. Terry1, Robert C. Hider2, Greg E. Mullen1, Philip J. 
Blower1  
1. Division of Imaging Sciences and Biomedical Engineering, King's College London, 
London, United Kingdom. 
2. Institute of Pharmaceutical Science, King's College London, London, United 
Kingdom. 
 
SUPPLEMENTAL METHODS 
All reagents and consumables were purchased from Sigma Aldrich (Dorset, UK) or 
Fischer Scientific (Loughborough, UK), with the exception of Fmoc-Lys-Dde-COOH 
(Bachem AG, Bubendorf Switzerland), PMPA (Enzo Life Sciences, Exeter, UK), 
DOTA-PSMA (PSMA-617) and HBED-CC-PSMA DKFZ-11, (ABX, Radeberg, 
Germany). SCID/Beige mice were purchased from Charles River, Margate, UK. 
DU145 and DU145-PSMA cells were provided by Dr Florian Kampier (1). These cells 
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were cultured in RMPI 1640 medium supplemented with 10 % FBS, 2 mM L-
glutamine and penicillin/streptomycin. To prepare for experiments cells were grown at 
37 °C in an incubator with humidified air equilibrated with 5 % CO2. 
Instrumentation 
1H and 13C NMR spectra were acquired on a Bruker Avance III 700 spectrometer 
operating at 700 MHz (1H frequency), equipped with a quadruple-resonance QCI 
cryoprobe. 
High resolution LC-ESI-MS was performed in positive ion mode on an Agilent 6520 
Accurate-Mass Q-TOF LC/MS connected to an Agilent 1200 HPLC.  
All HPLC utilized an Agilent 1200 LC with in-line radio (sodium iodide gamma 
detector) and UV detection (220 nm analytical, 280 nm preparative). Data were 
analyzed using Laura software (V.4.0.2.75 LabLogic Systems Ltd.).  
HPLC methods: Chemical purity of THP-PSMA and radiolabeling of 68/67Ga-THP-
PSMA were assessed using an Agilent Eclipse XDB C18 5 micron 4.6 x 150 mm 
column with an isocratic mobile phase (87.5 % H2O, 12.5 % ACN, 0.075 %TFA, 
0.05% TEA), with a flow rate of 1 mL/min. 
68/67Ga radiolabeling of HBED-CC-PSMA and DOTA-PSMA was assessed with the 
same HPLC equipment but an alternative mobile phase: A = H2O with 0.05 % TFA, B 
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= ACN with 0.05 % TFA, gradient: 0-5 minutes = 90 % A, 5-15 minutes = ramp to 50 
% B (4 % / min), 15-20 minutes = 90 % A, with a flow rate of 1 mL/min.  
Serum stability was assessed using size exclusion chromatography using a 
Phenomenex BioSep 5 µm SEC- s2000 column (300 × 7.8 mm) with PBS as the 
mobile phase and a flow rate of 1 mL/min. 
iTLC plates were scanned with a Lab-Logic mini-Scan TLC reader and analyzed with 
Laura software. Radioactivity counting was performed with a gamma counter (LKB 
Wallac, PerkinElmer, UK) for cell studies and in vivo biodistribution.  
iTLC methods: Radiolabeling for all 67/68Ga-PSMA radiotracers was assessed by iTLC 
utilizing Varian ITLC SGI0001 strips (10 cm length) with a mobile phase of 1 M 
ammonium acetate in water/methanol (1:1). 
Synthesis of THP PSMA 
Synthesis of H-Lys-(Dde)-2CT-resin (compound 3). 2-chlorotrityl resin (350 mg 
equivalent to a loading of 0.35 mmol) was inserted in a fritted polypropylene syringe 
and a solution of Fmoc-Lys-Dde-COOH (600 mg 1.1 mmol) (1, Supplemental Fig. 1) 
and excess DIPEA in DCM was added. After stirring overnight to form compound 2, 
the resin was washed with DCM and subsequently treated with methanol for 10 min. 
Thereafter, the resin was washed with DMF and DCM and finally dried under vacuum. 
Resuspension of the beads in a solution of piperidine/DMF (20% : 80%) for 20 min, 
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followed by separation of the resin from the supernatant by suction filtration and 
washing with DMF and DCM produced resin-bound compound 3. 
Synthesis of resin-bound THP-PSMA (compound 9). Bis(tert-butyl) ester L-
glutamate hydrochloride (444 mg, 1.5 mmol) was dissolved in anhydrous DCM (100 
mL) containing DIPEA (750 µL, 4.3 mmol). This solution was added dropwise to a 3-
neck round bottom flask containing a solution of triphosgene (150 mg, 0.5 mmol) in 
anhydrous DCM (5 mL) at 0 °C under a nitrogen atmosphere. The reaction solution 
was then allowed to warm to room temperature, and stirred for 1 hour. The previously 
prepared H-Lys-(Dde)-2CT-resin (3, Supplemental Fig. 1) (250 mg, equivalent to a 
loading of 0.25 mmol) was added and stirred overnight to form compound 6 
(Supplemental Fig. 1). The resin was separated from the supernatant by suction 
filtration in a fritted polypropylene syringe, washed and dried. The resin was 
suspended in a mixture of 2 % (v/v) hydrazine hydrate in 2 mL DMF and stirred for 15 
min, and then washed with DMF. This step was repeated 4 times to produce compound 
7 (Supplemental Fig. 1). Compound 7 (100 mg equivalent to a loading of 0.1 mmol) 
was added to a solution of glutaric anhydride (114 mg, 1 mmol) and DIPEA (358 µL, 2 
mmol) dissolved in 2 mL DMF, and the mixture stirred for 3 hours to produce 
compound 8 (Supplemental Fig. 1). Compound 8 (50 mg, equivalent to a loading of 
0.05 mmol) was suspended in a solution of HATU (20 mg, 0.05 mmol) and DIPEA (18 
µL, 0.1 mmol) in anhydrous DMF (0.5 mL) and in situ activation of the carboxylate 
was allowed to proceed for 10 minutes. A solution of THP-NH2 (70 mg, 0.09 mmol), 
synthesized by a previously published method (2), in DMF/DMSO (2.5 mL/2 mL) 
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containing DIPEA (18 µL, 0.1 mmol) was then added to this suspension, and stirred 
for 36 hours, to furnish compound 9 (Supplemental Fig. 1). 
Cleavage of THP-PSMA (compound 10) from the resin. Cleavage and removal of 
the side-chain protecting groups were performed by treating the resin-bound compound 
9 with TFA for 3 hours at RT in the presence of phenol (5 % w/v), water (5 % v/v) and 
TIPS (2 % v/v) as scavengers. The filtrate was collected and the resin washed with 
TFA and DCM. The solution was concentrated to < 0.5 mL at 40 °C under a gentle 
stream of nitrogen. Ice-cold diethyl ether was added to precipitate THP-PSMA (10, 
Supplemental Fig. 1). The suspension was centrifuged, the supernatant decanted off, 
the precipitate washed with diethyl ether, and finally dissolved in aqueous acetonitrile 
and lyophilized. Crude THP-PSMA was purified by semi-preparative RP-HPLC to 
give a TFA salt (C54H77N11O19.(CF3COO)3) MW = 1526.33. Semi-preparative reverse 
phase HPLC was conducted using an Agilent Eclipse XDB C18 5 micron 21.2 x 150 
mm column with the concentration of mobile phase B increasing at a rate of 1%/min 
(A = H2O with 0.2% TFA, B = acetonitrile (ACN) with 0.2% TFA, starting from 100% 
A at time 0, flow rate 5 mL/min).  
Yield of THP-PSMA(CF3COO)3: 4 mg, 2.6 µmol, 5.2% yield from resin loading. 
Analytical HPLC Rt = 13m 23s, > 98% purity. For analytical data see results section 
below. 
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SUPPLIMENTAL FIGURE 1: Reaction scheme for synthesis of THP-PSMA. a. 2-
chlorotrityl polymer bound resin beads, DIPEA, DCM; b. Piperidine, DMF; c. 
Triphosgene, DIPEA, DCM, 0 °C; d. Compound 3, Compound 5, DCM; e. Hydrazine 
hydrate, DMF; f. Glutaric anhydride, DIPEA, DMF; g. THP-NH2, HATU, DIPEA, 
DMF, DMSO; h. TFA, phenol, TIPS, H2O 
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Radiolabeling  
68/67Ga radiolabeling of HBED-CC-PSMA and DOTA-PSMA was assessed with the 
same HPLC equipment but an alternative mobile phase: A = H2O with 0.05 % TFA, B 
= ACN with 0.05 % TFA, gradient: 0-5 minutes = 90 % A, 5-15 minutes = ramp to 50 
% B (4 % / min), 15-20 minutes = 90 % A, with a flow rate of 1 mL/min.  
iTLC methods: Radiolabeling for all 67/68Ga-PSMA radiotracers was assessed by iTLC 
utilizing Varian ITLC SGI0001 strips (10 cm length) with a mobile phase of 1 M 
ammonium acetate in water/methanol (1:1). 
Conversion of 67Ga-citrate solution to 67Ga-chloride in 0.1 M HCl  
Conversion of 67Ga-citrate to 67Ga-chloride is required as the presence of citrate 
reduces the radiolabeling efficiency of 67Ga with a number of chelators (3,4). 67Ga-
citrate (6.49 mM citrate Mallinckrodt, Switzerland) was passed over a Silica Light 
Sep-Pak cartridge (120 mg sorbent, 55-105 µm particle size) at 1 mL/min to capture 
the radio-metal on the cartridge. This process was repeated 3 times whereupon ~ 90% 
of the activity remained on the cartridge. After washing with 5 mL dH2O the 67Ga was 
eluted with 400 µL 0.1M HCl and collected in 50 µL fractions. Fractions with the 
highest activity concentration (75 MBq/50 µL were used for labeling (activity 
concentration 1.5 GBq/mL).  
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Preparation of 67Ga and 68Ga PSMA tracers:  
Before addition to cells the tracer was diluted to 50 nM in PBS 
67Ga-THP-PSMA for in vitro studies: 10 µL 2 mg/mL solution (20 µg, 13.1 nmol 
THP-PSMA (MW 1526.33)) was added to 50 µL 67Ga in 0.1M HCl (converted from 
67Ga citrate), and the pH adjusted to 6.5 - 7.5 with 4.5 µL 1M sodium bicarbonate. 
Labeling was assessed after 5 min at room temperature by iTLC and HPLC. Before 
addition to cells the tracer was diluted to 50nM in PBS. 
DOTA-PSMA for in vitro studies: 50 µL 67Ga or 68Ga in 0.1M HCl, 5.25 µL 1M HCl 
and 20 µL 2.1M HEPES were combined, producing a solution at pH 3.5. For 67Ga 
labeling 20 µg (13.3 nmol) DOTA-PSMA (ABX, MW 1498.18) was added; for 68Ga 
labeling 2 µg (1.3 nmol) DOTA PSMA was added. The solution was heated to 95°C 
for 30 minutes and then labeling was assessed by iTLC and HPLC. Before addition to 
cells the tracer was diluted to 50nM in PBS. 
HBED-CC-PSMA for in vitro studies: 50 µL 67Ga or 68Ga in 0.1M HCl, 5 µL 1M 
HCl and 50 µL 2.1M HEPES were combined, producing a solution at pH 4.5. For 67Ga 
labeling 29 µg (20.6 nmol) HBED-CC-PSMA (ABX, MW 1403.09) was added; for 
68Ga labeling 2 µg (1.4 nmol) HBED-CC-PSMA was added. The solution was heated 
to 95°C for 10 minutes and then labeling was assessed by iTLC and HPLC. Before 
addition to cells the tracer was diluted to 50nM in PBS. 
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HBED-CC-PSMA for in vivo studies: 68Ga eluate (200 µL, 35-50 MBq) was added 
to a pre-prepared solution of HBED-CC-PSMA (15 µL, 105 µM, 2.2 µg HBED-CC-
PSMA) and sodium bicarbonate (19 µL, 1 M), and heated at 90 °C for 10 min (pH 3 – 
4). A radiochemical yield of > 95% was consistently achieved.  
Preparation of natGa chelated PSMA tracers: 
natGa-THP-PSMA: 124 µL of 0.93 mM THP-PSMA was added to 93 µL 6.4 mg/mL 
natGa(NO3)3.X(H2O) dissolved in 0.1M HCl (a 20-fold excess of gallium over THP-
PSMA). The pH was adjusted to 6.5-7.5 with 14 µL 1M sodium bicarbonate, and 231 
µL PBS was then added. The solution was sonicated for 15 minutes. This produced a 
final solution of 0.25 mM natGa-THP-PSMA. This solution was diluted in PBS to 
produce the range of concentrations required for the IC50. This complex was 
characterized with LC-ESI-MS: m/z [C54H74N11O19Ga + H]+ observed monoisotopic 
peak = 1250.45092 calculated = 1250.44909. [C54H74N11O19Ga + 2H]2+ observed 
monoisotopic peak = 625.72846, calculated = 625.72818.  
natGa-HBED-CC-PSMA: 124 µL of 0.93 mM HBED-CC-PSMA was added to 93 µL 
of 6.4 mg/mL natGa(NO3)3.X(H2O) dissolved in 0.1M HCl (a 20-fold excess of gallium 
over HBED-CC-PSMA). The pH was adjusted to 4 with 13 µL 1M sodium bicarbonate 
and the solution was heated to 95°C for 10 min. The pH was adjusted to 6.5-7.5 with 
1M sodium bicarbonate followed by sonication for 15 minutes. This produced a final 
solution of 0.5 mM natGa-HBED-CC-PSMA. This solution was diluted in PBS to 
produce the range of concentrations required for the IC50. 
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IC50 measurement protocol  
0.25 x 106 cells/well were seeded in a 24-well plate, one day before the assay. 
Increasing concentrations of natGa-THP-PSMA or natGa-HBED-CC-PSMA followed by 
1nM 68Ga-DOTA-PSMA (specific activity 5 - 7.5MBq/nmole, diluted in PBS) was 
added to the cells (total volume 250 µL). After 30 minutes incubation at 37 °C, the 
cells were washed with PBS (3 × 0.25 mL), lysed with NaOH (1 M, 0.25 mL) and the 
wells washed with PBS (0.25 mL). The activity present in supernatant and lysate were 
measured by gamma counting. Data was analyzed using Graph Pad Prism and a one 
site – fit log IC50 algorithm. 
Relative affinity measurements 
DU145-PSMA cells were seeded with 1.5 x 106 cells/well in a 6 well plate, one day 
before the assay. Two minutes prior to incubation with tracer, the cell medium was 
replaced by 1410 µL fresh medium at 4°C. 30µL of 67Ga-PSMA tracer (50 nM, 
specific activity 0.75 - 2.2 MBq/nmol), and 30µL 68Ga-PSMA tracer (50 nM, specific 
activity 4 - 26 MBq/nmol, diluted in PBS) and 30 µL PBS were added, giving a total 
volume of 1.5 mL and final concentrations of 1 nM 67Ga PSMA tracer and 1nM 68Ga 
PSMA tracer (total labeled and unlabeled PSMA conjugate concentration 2 nM). 
Additionally non-specific uptake was determined by using non-PSMA expressing cells 
(DU145) or by blocking PSMA expressing cells (DU145-PSMA) with 750 µM PMPA. 
After 2 hours incubation at 4°C, the cells were washed with 3 × 0.25 mL 4°C PBS to 
determine the unbound fraction, then incubated with 0.5 M glycine pH 2.5 at 4°C for 5 
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minutes to determine the cell surface bound fraction, and then lysed with 1 M NaOH 
and the well washed with PBS to determine the fraction internalized by the cells. The 
activity from the 67Ga-PSMA tracer and the 68Ga-PSMA tracer present in each fraction 
was measured by gamma counting (68Ga values were corrected for 67Ga component 
and 67Ga was measured once 68Ga had decayed > 10 half-lives). Specific binding was 
calculated by subtracting the non-specific binding (binding of the tracer to DU145 cells 
or to DU145-PSMA cells in the presence of PMPA) from the total binding percentage 
of activity associated with the DU145-PSMA cells when no blocking agent is present. 
Ratios of specific binding were calculated pair-wise for tracers incubated in the same 
well. 
Imaging protocol:  
PET-CT acquisition: The PET-CT scans were performed on a BioScan nanoPET-CT 
PLUS (Mediso, Hungary) scanner using their proprietary acquisition software (Nucline 
v 2.00). CT was performed with an X-ray tube voltage of 45 kVp, 600 ms of exposure 
time and 360° projections. This scan took 10 minutes to perform. Dynamic PET scans 
were performed within a 94.7 mm field of view from 0 min to 60 min post tail vein 
injection of the 68Ga-PSMA tracer. Acquisition took place in 1–5 coincidence mode 
with a coincidence window of 5 ns and a 400–600 keV energy window.  
Image analysis: 
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The dynamic PET data were reconstructed using Nucline software (v 2.00). Data were 
allocated to both 20 min and 2 min bins using 0.4 mm3 voxels for PET and 0.21 mm3 
for CT. Image processing and analysis were performed using Vivoquant software (v 
1.23). Before analysis both CT and PET images were realigned, processed to a voxel 
size of 0.21 mm3 and the PET output calibrated to display MBq per voxel. Regions of 
interest (ROIs) for each data file were produced using three different techniques: Fixed 
volume ROIs, Otsu thresholding and freehand segmentation from the CT image. Fixed 
volume ROIs were used for muscle (17.2 mm3 sphere within the thigh muscle), and 
blood pool (2.2 mm3 sphere in left ventricle). These ROIs were positioned manually 
and drawn in triplicate within each organ. Otsu thresholding was used to determine the 
total activity deriving from the kidneys or the bladder. This method was not suitable 
for tumor uptake due to the close proximity of kidney signal. Total tumor volume was 
drawn manually from the CT image, defined three times per animal and the average 
value from these three ROIs determined. %ID/cm3 values for each ROI were calculated 
using the activity and volume of the ROI and the ID as the total activity within the 
image, excluding activity within the tail. Time-activity curves were produced from the 
2 min bins and total uptake was determined from the 20 min binned data at the 40 - 60 
min time point. Static images were produced from dynamic data between 40 - 60 min 
and scaled between 0 and 25 % ID / cm3. 
Biodistrubution studies 
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Additional 68Ga(THP-PSMA) biodistribution and blocking studies were performed in 
mice bearing DU145 or DU145-PSMA tumors without imaging or continuous 
anesthesia. 68Ga(THP-PSMA) (3.5 – 12.7 MBq, 0.7 -0.9 µg THP-PSMA) was 
administered via tail vein injection under isoflurane anesthesia. After injection 
anesthesia ceased and 1 hour PI the animals were euthanized by cervical dislocation 
and organs harvested, weighed and counted (n=3 for each group). 
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SUPPLEMENTAL RESULTS 
1H NMR: (D2O, 700 MHz) 1.37 (m, 2H), 1.50 (m, 2H), 1.7 (m, 1H), 
1.78 (m, 2H), 1.85 (m, 1H), 1.92 (t, J = 
8.09, 6H), 1.96 (m, 1H), 2.14 (m, 1H), 2.18 
(q, J= 6.59, 4H), 2.22 (t, J = 8.09, 6H), 2.35 
(t, J =6.64, 2H), 2.49 (t, J = 7.49, 2H), 2.57 
(s, 9H), 3.13 (t, J = 6.98, 2H), 3.36 (t, J = 
6.64, 2H), 3.91 (s, 9H), 4.15 (dd, J = 8.99, 
5.59 1H), 4.23 (dd, J = 8.70, 4.97 1H), 4.67 
(s, 9H), 7.00 (s, 3H) 
13C NMR: (D2O, pH 3, 175 MHz) 20.5, 21.9, 22.4, 26.5, 27.8, 29.3, 29.4, 
30.1, 30.7, 34.8, 35.5, 35.9, 36.1, 38.5, 
39.0, 52.8, 113.6, 138.1, 143.2, 149.9, 
159.4, 161.0, 173.2, 175.5, 175.7, 176.2, 
176.6, 177.4 
ESI-MS: m/z [C54H77N11O19 + H]+  observed monoisotopic peak = 1184.5494      
calculated = 1184.5475 
ESI-MS: m/z [C54H77N11O19 + 2H]+2 observed monoisotopic peak = 592.7768, 
calculated = 592.7788 
ESI-MS: m/z [C54H77N11O19 + 3H]+3 observed monoisotopic peak = 395.5202, 
calculated = 395.5221 
m/z [C54H74N11O19Ga + H]+ observed monoisotopic peak = 1250.45092 
calculated = 1250.449102 
m/z [C54H74N11O19Ga + 2H]+2 observed monoisotopic peak = 625.72846, 
calculated = 625.72819 
 
SUPPLEMENTAL TABLE 1: 1H NMR, 13C NMR and ESI-MS data for THP-PSMA 
confirming its identity. 
 
 
  
by NYU Med Ctr Lib - Periodicals Dept on April 13, 2017. For personal use only. jnm.snmjournals.org Downloaded from 
15 
 
 
SUPPLEMENTAL FIGURE 2: Radiochemical purity as measured by iTLC of 68Ga-
THP-PSMA labeled with 5mL one step kits as a function of incubation time at room 
temperature, with both an IRE generator and an E&Z generator. Broken red line 
represents quality control threshold of 95% (n=3, mean ± SD) 
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Serum Stability: 
 
SUPPLEMENTAL FIGURE 3. Size exclusion HPLC chromatograms of (A) 68Ga-
THP-PSMA; (B) 68Ga-THP-PSMA after 6 hours incubation in human serum at 37°C; 
<2% transchelation to serum (C) 67Ga-THP-PSMA after 8 days incubation in human 
by NYU Med Ctr Lib - Periodicals Dept on April 13, 2017. For personal use only. jnm.snmjournals.org Downloaded from 
17 
 
serum at 37°C <5% transchelation to serum (D) 68Ga3+ incubated in human serum for 6 
hours. All chromatograms have been decay corrected.  
Cell Uptake and Binding Affinity Assays 
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SUPPLEMENTAL FIGURE 4: Uptake of 1nM 67Ga-HBED-CC-PSMA 67Ga-
DOTA-PSMA and 67Ga-THP-PSMA over time at 4°C and 37°C, 1 × 106 cells/mL. 
Combined internalized and cell surface bound activity DU145-PSMA cells (blue); 
internalized activity DU145-PSMA cells (black); internalized and cell surface bound 
activity DU145 cells (red). (n=4, mean ± SD) per time point per tracer. 
 
SUPPLEMENTAL FIGURE 5: Representative IC50 experiments for natGa-THP-
PSMA and natGa-HBED-CC-PSMA with 1nM 68Ga-DOTA-PSMA as the probe. (n=4) 
for each concentration. IC50 values in main text are the mean of at least 3 experiments. 
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SUPPLEMENTAL FIGURE 6. Time activity curves of SCID beige mice bearing 
DU145-PSMA tumors, derived from PET imaging data from mice imaged with 68Ga-
THP-PSMA or 68Ga-HBED-CC-PSMA during one hour post injection. Plotted data is 
the mean and standard deviation of three mice calculated from the total % ID in the 
kidneys and bladder combined. 
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         68Ga-THP-PSMA       68Ga-HBED-CC-PSMA 
 
Tumor type  
Group 1 
DU145-PSMA 
Group 4 
DU145 
Group 3 
DU145-PSMA  
Group 2 
DU145-PSMA 
     Blocked PMPA    
     (n=3) (n=3) (n=3)    (n=3) 
Tumor    16.4 ± 7.4 0.69 ± 0.7 1.40 ± 0.2    19.5 ± 7.6 
Blood  0.73 ± 0.4 1.23 ± 1.7 1.11 ± 0.7  2.18 ± 1.2 
Intestines    0.35 ± 0.1 0.64 ± 0.6 0.71 ± 0.3    1.20 ± 0.5 
Kidney  40.4 ± 34 52.3 ± 77 5.20 ± 5.0  63.4 ± 23 
Liver    0.45 ± 0.2 0.59 ± 0.7 0.60 ± 0.2    0.69 ± 0.1 
Lungs  0.50 ± 0.2 0.94 ± 1.3 0.72 ± 0.3  1.29 ± 0.4 
Muscle    0.51 ± 0.4 0.31 ± 0.4 0.21 ± 0.1    0.26 ± 0.1 
Salivary glands  0.28 ± 0.1 0.48 ± 0.7  0.33 ± 0.2  0.76 ± 0.1 
Spleen    3.70 ± 1.3 3.61 ± 3.1 0.75 ± 0.1    17.6 ± 6.1 
Tumor to organ ratios        
Tumor to blood    30.8 ± 28 0.93 ± 0.4 1.64 ± 0.9   11.0  ± 6.0 
Tumor to muscle  44.6  ± 28 3.16 ± 1.1 9.79 ± 6.8  77.0  ± 34 
Tumor to spleen    4.38  ± 0.8 0.17 ± 0.1 1.87 ± 0.3   1.16 ± 0.42 
 
SUPPLEMENTAL TABLE 2. Ex vivo biodistribution at 1 hour post injection for 
PET-imaged mice. Mice bearing DU145-PSMA tumors were injected with 68Ga-THP-
PSMA, 68Ga-THP-PSMA plus blocking agent PMPA, or 68Ga-HBED-CC-PSMA. 
Mice bearing control DU145 tumors were imaged with 68Ga-THP-PSMA only. 
by NYU Med Ctr Lib - Periodicals Dept on April 13, 2017. For personal use only. jnm.snmjournals.org Downloaded from 
21 
 
ABBREVIATIONS 
ACN - acetonitrile 
DCM – dichloromethane 
Dde - N-(1-(4,4-dimethyl-2,6-dioxocyclohexylidene)ethyl);  
DIPEA - N,N-diisopropylethylamine 
DMF dimethylformamide 
DMSO - dimethyl sulfoxide 
Fmoc - fluorenylmethyloxycarbonyl 
HATU - (1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-
oxid hexafluorophosphate) 
Lys - Lysine 
PBS- Phosphate-buffered saline 
PMPA – 2-(phosphonomethyl)pentane-1,5-dioic acid  
PSMA – Prostate specific membrane antigen  
TEA - triethanolamine  
TFA - trifluoroacetic acid 
THP - tris(hydroxypyridinone) 
TIPS – triisopropylsilane 
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